Year: 2020
Type: review
Abstract: Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.
Authors: Xiaodan Yao, Jaffer A. Ajani, Shumei Song
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G1299882215, Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha, G3049237521, The Role of Telomere Shortening in MDS-AML Pathogenesis (resubmission), G6678286902, Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus Cancer, Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction, G8444441947
OpenAlex ID: W3007046246